Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis

Hamad Almutlaq · 2026

Read Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis by Hamad Almutlaq (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13510228.txt.

Description

Hamad Almutlaq reviews real-world use of upadacitinib for stubborn eczema at one Saudi hospital. The oral drug blocks a Janus kinase tied to immune overdrive. Middle East clinic data on it remain scarce. Records covered thirty patients treated between 2023 and 2025.

Twenty-eight had follow-up clear enough to judge response. Doctors logged improvement in twenty-seven of those patients. Most responses showed within four weeks of starting. Itch and sleep scores each fell from a median of eight to two. Five patients stopped the drug, two of them over safety or lab worries. Careful picking and close lab watch are the author's advice.

Catalog record

CREATORHamad Almutlaq
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13510228

Browse the full library · About the Tower of Babel